Understanding Tepati: Long-Term Data from the Surmount Trials

Welcome to the Docks Who Lift podcast, where we simplify the complexities of a healthy lifestyle, exercise medicine, and weight loss. In this episode, we dive deep into the latest findings from the Surmount trials, specifically focusing on Tepati (Zepbound), a GLP-1 drug approved for obesity management. Join us as we discuss the implications of long-term data and its impact on pre-diabetes and weight management.

The Latest on Tepati and the Surmount Trials

This week, we reflected on our experiences at Obesity Week, a conference where leading obesity researchers present groundbreaking data. One key highlight was the long-term results of the Surmount trials, which extended beyond the initial 72 weeks to show results over three years and four months. This data focuses specifically on individuals with pre-diabetes, providing insights into the efficacy of Tepati in a real-world context.

What is Tepati?

Tepati, also known as Zepbound, is a GLP-1 GIP co-agonist. It works similarly to semaglutide but shows higher weight loss percentages in certain populations. The trials indicate that Tepati can lead to significant total body weight loss, with some participants achieving a weight reduction of over 20% over the study period.

Understanding Pre-Diabetes

Pre-diabetes is a crucial condition to address, as it signifies a transition to type 2 diabetes. The criteria for pre-diabetes include:

• Hemoglobin A1c of 5.7% to 6.4%
• Fasting blood glucose between 100 and 125 mg/dL
• 2-hour glucose tolerance test results of 140 to 199 mg/dL

Individuals with pre-diabetes have a significantly increased risk of progressing to type 2 diabetes, making it essential to manage this condition effectively.

Key Findings from the Surmount Trials

The Surmount trials provided compelling evidence regarding the long-term benefits of Tepati in individuals with pre-diabetes:

• Weight loss of 15% to 23% was observed across different doses of Tepati, with participants maintaining this weight loss over time.
• Incidence of type 2 diabetes was significantly reduced, showing a 94% risk reduction among those treated with Tepati compared to the placebo group.
• Despite some participants experiencing an increase in appetite, they managed to maintain their weight loss, highlighting the drug's efficacy.

Potential Side Effects

As with any medication, Tepati has potential side effects, the most common being nausea and constipation. The long-term data indicates:

• Nausea rates decreased over time, with 30% of participants in the 10 mg dose reporting nausea initially.
• Constipation was prevalent, emphasizing the need for dietary adjustments to maintain gastrointestinal health.
• Serious adverse events were minimal, with no significant differences in pancreatitis rates between the treatment and placebo groups.

The Importance of Lifestyle Changes

While medications like Tepati provide significant benefits, lifestyle changes remain critical for overall health. The combination of medication and lifestyle interventions can yield the best outcomes for individuals struggling with obesity and pre-diabetes.

Conclusion

Tepati represents a promising option for individuals with pre-diabetes and obesity, showing significant long-term benefits in weight management and diabetes prevention. However, it is vital to continue promoting lifestyle changes alongside medication to optimize health outcomes. Understanding the role of GLP-1 drugs like Tepati in the broader context of weight management is essential for effective patient care.